A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Charite Universitaetsmedizin Berlin /ID# 215287, Berlin

Greenville Health System Cance /ID# 216059, Greenville

Masonic Cancer Center /ID# 216101, Minneapolis

Joliet Oncology-Hematology Associates, LTD /ID# 215051, Joliet

Universitaetsklinik Heidelberg /ID# 214679, Heidelberg

Universitatsklinikum Tubingen /ID# 217021, Tübingen

MD Anderson Cancer Center /ID# 214867, Houston

Utah Cancer Specialists /ID# 215375, Salt Lake City

Universitaetsklinikum Ulm /ID# 214678, Ulm

Swedish Cancer Institute /ID# 216120, Seattle

Massachusetts General Hospital /ID# 214833, Boston

Dana-Farber Cancer Institute /ID# 214832, Boston

Memorial Sloan Kettering Cancer Center /ID# 214886, New York

University of Pennsylvania /ID# 216357, Philadelphia

Vanderbilt University Med Ctr /ID# 213852, Nashville

Aichi Cancer Center Hospital /ID# 224527, Nagoya

Pan American Center for Oncology Trials, LLC /ID# 216862, Rio Piedras

GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan